Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Rutten H) > Patient Heterogenei...

Hoogendoorn, MartineErasmus University Rotterdam (författare)

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease : Are Current Models Suitable to Evaluate Personalized Medicine?

Artikel/kapitelEngelska2016

Förlag, utgivningsår, omfång ...

Elsevier BV,2016
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:umu-128137
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-128137URI
https://doi.org/10.1016/j.jval.2016.04.002DOI
https://lup.lub.lu.se/record/d3980d87-6687-4483-b684-c0753eb85e46URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

OBJECTIVES: To assess how suitable current chronic obstructive pulmonary disease (COPD) cost-effectiveness models are to evaluate personalized treatment options for COPD by exploring the type of heterogeneity included in current models and by validating outcomes for subgroups of patients.METHODS: A consortium of COPD modeling groups completed three tasks. First, they reported all patient characteristics included in the model and provided the level of detail in which the input parameters were specified. Second, groups simulated disease progression, mortality, quality-adjusted life-years (QALYs), and costs for hypothetical subgroups of patients that differed in terms of sex, age, smoking status, and lung function (forced expiratory volume in 1 second [FEV1] % predicted). Finally, model outcomes for exacerbations and mortality for subgroups of patients were validated against published subgroup results of two large COPD trials.RESULTS: Nine COPD modeling groups participated. Most models included sex (seven), age (nine), smoking status (six), and FEV1% predicted (nine), mainly to specify disease progression and mortality. Trial results showed higher exacerbation rates for women (found in one model), higher mortality rates for men (two models), lower mortality for younger patients (four models), and higher exacerbation and mortality rates in patients with severe COPD (four models).CONCLUSIONS: Most currently available COPD cost-effectiveness models are able to evaluate the cost-effectiveness of personalized treatment on the basis of sex, age, smoking, and FEV1% predicted. Treatment in COPD is, however, more likely to be personalized on the basis of clinical parameters. Two models include several clinical patient characteristics and are therefore most suitable to evaluate personalized treatment, although some important clinical parameters are still missing.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Hälsovetenskap Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi hsv//swe
MEDICAL AND HEALTH SCIENCES Health Sciences Health Care Service and Management, Health Policy and Services and Health Economy hsv//eng
COPD
model
patient heterogeneity
validation
COPD
model
patient heterogeneity
validation

Biuppslag (personer, institutioner, konferenser, titlar ...)

Feenstra, Talitha LUniversity of Groningen,National Institute for Public Health and the Environment (RIVM) (författare)
Asukai, YumiIMS Health Sweden AB (författare)
Briggs, Andrew HUniversity of Glasgow (författare)
Borg, SixtenLund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics,Evidera Ltd(Swepub:lu)med-sxb (författare)
Dal Negro, Roberto WNational Center for Respiratory Pharmacoeconomics and Pharmacoepidemiology (författare)
Hansen, Ryan NUniversity of Washington (författare)
Jansson, Sven-ArneUmeå University,Umeå universitet,Yrkes- och miljömedicin,The OLIN Unit(Swepub:umu)svja0005 (författare)
Leidl, ReinerHelmholtz Zentrum München (författare)
Risebrough, NancyICON Health Economics (författare)
Samyshkin, YevgeniyIMS Health Sweden AB (författare)
Wacker, Margarethe EHelmholtz Zentrum München (författare)
Rutten-van Mölken, Maureen P M H (författare)
Erasmus University RotterdamUniversity of Groningen (creator_code:org_t)

Sammanhörande titlar

Ingår i:Value in Health: Elsevier BV19:6, s. 800-8101098-30151524-4733

Internetlänk

Hitta via bibliotek

Value in Health (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Hoogendoorn, Mar ...; Feenstra, Talith ...; Asukai, Yumi; Briggs, Andrew H; Borg, Sixten; Dal Negro, Rober ...; visa fler...; Hansen, Ryan N; Jansson, Sven-Ar ...; Leidl, Reiner; Risebrough, Nanc ...; Samyshkin, Yevge ...; Wacker, Margaret ...; Rutten-van Mölke ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Hälsovetenskap; och Hälso och sjukvå ...

Artiklar i publikationen: Value in Health

Av lärosätet: Umeå universitet; Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se